Spero Therapeutics, Inc. revenue
Spero Therapeutics, Inc.'s revenue was $66.8m in fiscal 2025, up 39.2% on the year before. Since fiscal 2016 ($335,000) it has grown at a compound 80.1% a year. Over the last twelve months it was $47.0m.
Revenue history
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 | 4 | 18 | 9 | 18 | 54 | 104 | 48 | 67 | 47 |
| Growth on the year before | — | +490.7% | +100.4% | +357.6% | −48.6% | +95.7% | +193.1% | +94.0% | −53.8% | +39.2% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Collaboration Revenue Related Party | $47M | 70.4% | ▲ 74.0% |
| Collaboration Revenue | $12.6M | 18.8% | ▲ 3292.5% |
| Grant Revenue | $7.2M | 10.8% | ▼ 65.1% |
From Spero Therapeutics, Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Spero Therapeutics, Inc. | $47.0m | -3.3% | -4.7% |
| Editas Medicine, Inc. | $47.0m | 20.8% | 34.5% |
| Sutro Biopharma, Inc. | $45.7m | -56.3% | -7.0% |
| Ocular Therapeutix, Inc | $52.1m | -8.1% | -1.6% |
| Lexicon Pharmaceuticals, Inc. | $41.5m | -29.0% | 366.7% |
| Gossamer Bio, Inc. | $53.3m | 32.4% | — |
Compare with peers
- Editas Medicine, Inc. revenue
- Sutro Biopharma, Inc. revenue
- Ocular Therapeutix, Inc revenue
- Lexicon Pharmaceuticals, Inc. revenue
- Gossamer Bio, Inc. revenue
Head to head: EDIT vs SPROSPRO vs STROOCUL vs SPRO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies